Certificaations & IP

The CL-K1 technology platform is supported by strain deposits, granted patents, international patent filings, and market-specific regulatory documentation. Status is presented by category to distinguish granted rights from pending applications and product-level notifications.

Certifications & Intellectual Property

Regulatory recognition and patent protection supporting CL-K1® and EFILA.

CL-K1® and EFILA are supported by regulatory milestones, product notification records, and intellectual property assets across Korea, Singapore, Malaysia, China, Macau, and international patent pathways.

4Regulatory and product notification milestones
7Patent and PCT certificate documents displayed
PCTInternational pathway obtained, with U.S. application pending

Certification and regulatory recognition

These milestones reflect the regulatory and market-entry progress of Ceriporia lacerata, CL-K1®, and EFILA-related product applications in key Asian markets.

KoreaFunctional ingredient

Ceriporia lacerata recognized as a Health Functional Food Ingredient

Ceriporia lacerata has received recognition in Korea as a health functional food ingredient, supporting its use within regulated functional food development pathways.

Status: Recognized in KoreaScope: Health functional food ingredient pathway
KoreaNovel food ingredient

CL-K1® recognized as a Food Ingredient / Novel Food Ingredient

CL-K1® has obtained Korean food ingredient recognition, supporting its position as a standardized natural-origin ingredient platform.

Status: Recognized in KoreaScope: Food ingredient / novel food ingredient pathway
SingaporeHSA voluntary notification

EFILA products notified under the HSA Voluntary Notification Scheme

EFILA Blood Sugar Support Jelly and EFILA Advance Blood Sugar Support have been notified under Singapore's HSA voluntary notification scheme.

EFILA Blood Sugar Support Jelly: VNS-2026-01-00049EFILA Advance Blood Sugar Support: VNS-2025-07-00175
MalaysiaMarket-entry progress

EFILA Blood Sugar Support Jelly - regulatory progress in Malaysia

EFILA Blood Sugar Support Jelly has obtained Malaysia-related regulatory classification / approval progress as part of its broader market-entry pathway.

Product: EFILA® Liquid Jelly in SachetMarket: Malaysia

Intellectual property portfolio

Patent certificate documents are displayed directly for review, with each certificate paired with its patent title and jurisdiction.

KoreaCL-K1®

Novel strain of Ceriporia lacerata-K1 and culture composition

Novel strain of Ceriporia lacerata-K1 and culture composition certificate

Patent No. 10-1925890 · Korea

KoreaCL-K1®

Two-stage cultivation composition for metabolic application

Two-stage cultivation composition for metabolic application certificate

Patent No. 10-1969433 · Korea

KoreaCL-K1®

Two-stage cultivation composition for liver-related research

Two-stage cultivation composition for liver-related research certificate

Patent No. 10-1981571 · Korea

KoreaIrpex lacteus f.k.

Cultured broth of Irpex lacteus mycelium and composition

Cultured broth of Irpex lacteus mycelium and composition certificate

Patent No. 10-2380296 · Korea

ChinaIrpex lacteus f.k.

Irpex lacteus f.k. patent protection in China

Irpex lacteus f.k. patent protection in China certificate

Patent No. ZL 2022 8 0003976.7 · China

MacauIrpex lacteus f.k.

Irpex lacteus f.k. patent protection in Macau

Macau patent registration certificate

Patent No. J/008669 · Macau

PCTInternational

PCT international patent pathway

PCT international patent pathway certificate

PCT/KR2022/008072 · International pathway

Additional IP pathway: U.S. patent application is currently pending for the related strain pathway.

Regulatory status, permitted claims, product classifications, and approved uses may vary by jurisdiction. The information on this page is provided for corporate, scientific, and partnership communication purposes and does not constitute medical advice, treatment claims, or a guarantee of product approval in any market.